Results 91 to 100 of about 1,005,947 (300)

Somatic Evolution of a Germline Antibody Expands its Breadth to Neutralize Early SARS‐CoV‐2 Omicron Variants

Advanced Science, EarlyView.
Engineering of the 148‐germline (148‐GL) antibody reveals a roadmap for overcoming SARS‐CoV‐2 viral escape. By introducing four specific somatic hypermutations, the resulting 148‐M4 variant restores potent neutralization against Omicron BA.1 and BA.4/5.
Huibin Lv, Ziqi Feng, Qi Wen Teo, Chunke Chen, Akshita B. Gopal, Danbi Choi, Timothy J. C. Tan, Yun Sang Tang, Lewis Siu, Armita Nourmohammad, Roberto Bruzzone, Ian A. Wilson, Meng Yuan, Nicholas C. Wu, Chris K. P. Mok   +14 more
wiley   +1 more source

Evaluation of Neonatal Sprague-Dawley Rats as a Potential Animal Model for the Neurovirulence Test of an Iranian Mumps Vaccine Strain, RS-12 [PDF]

Archives of Razi Institute
Introduction: Mumps virus (MuV), a neurotropic member of paramyxoviridae, causes mumps disease. Since the 1960s, when the first live-attenuated vaccine against the MuV was developed, mumps outbreaks have dramatically decreased.
Mohammad kazem Shahkarami, Mohammad Taqavian, Mohammad Hasan Hablolvarid, Ashraf Mohammadi, Abolhasan Foroughi, Reza Shahbazi, Mazyar ShahKarami, Ali Reza Yousefi   +7 more
doaj   +1 more source

Understanding viral vector COVID-19 vaccines [PDF]

Updated Mar. 14, 2022What You Need to Know\u2022 Viral vector vaccines use a modified version of a virus that is different from the virus being targeted to deliver important instructions to our cells.

core  

PROTAC‐Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy

Advanced Science, EarlyView.
A PROTAC‐functionalized protein/DNA‐integrated nanoantigen platform is developed to enhance dendritic cell vaccine potency. By combining a VHL‐recruiting peptide‐modified antigen with a sustained expression plasmid within CaCO3 nanoparticles, this system amplifies cross‐presentation, promotes DC maturation, and elicits robust Th1 and CTL responses ...
Peng Liu, Qiang Chen, Zhe Zhou, Yuekang Xu, Jinyao Li   +4 more
wiley   +1 more source

Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial

Human Vaccines & Immunotherapeutics
We conducted a randomized, Phase 2 trial to assess the safety and humoral immunogenicity of reduced doses/dose volume of the standard dose of Ad26.COV2.S COVID-19 vaccine (5 × 1010 viral particles [vp]) in healthy adolescents aged 12–17 years ...
Jelena Tica, Veronica V. Rezelj, Benoit Baron, Vitalija van Paassen, Javier Zaidman, Lee Fairlie, Gert Scheper, Mathieu Le Gars, Frank Struyf, Macaya Douoguih, Javier Ruiz-Guiñazú   +10 more
doaj   +1 more source

Canonical Antibodies Adopt Distinct Binding Modes to Recognize Viral Glycan Shields

Advanced Science, EarlyView.
Canonical Y‐shaped antibodies recognize viral glycan shields through adaptive Fab assembly states shaped by glycan organization and somatic hypermutation. Structural analyses ofbroadly neutralizing antibodies VRC35 and VRC36 across glycoproteins of HIV‐1, influenza, SARS‐CoV‐2, and Lassa viruses reveal distinct Fab assembly states, spanning monovalent,
Jiaxuan Cheng, Evan M. Cale, Amirabbas Maghsoudi, Matthew S. Sutton, Nancy S. Longo, Rebecca A. Gillespie, Lingshu Wang, Ivan Kosik, Sue Chong, Atsuhiro Yasuhara, Tatsiana Bylund, Arne Schön, Prabhanshu Tripathi, Yaroslav Tsybovsky, Haotian Lei, Nicholas C. Morano, Allison B. Lupatkin, Abraham J. Morton, Zabrina C. Lang, Jordan E. Becker, Isabella R. Frascilla, Myungjin Lee, Ning Li, Cuiping Liu, Ryan S. Roark, Chen‐Hsiang Shen, I‐Ting Teng, David J. Van Wazer, Danyi Wang, Lingyuan Wu, Goran Ahlsen, Mike Castro, Haijuan Du, Michael J. Ernandes, Tiansheng Li, Bob C. Lin, Mark K. Louder, Krisha McKee, Jonah S. Merriam, Sijy O'Dell, Li Ou, Sergei Pletnev, David Prikryl, Qi Qiu, Sarah Rubin, Mallika Sastry, Stephen D. Schmidt, Asif Shajahan, Andrea R. Shiakolas, Sanjay Srivatsan, Baoshan Zhang, Qiong Zhou, Mark Connors, Jason G. Gall, Yicheng Guo, Rick K. Huang, Yaoxing Huang, Richard A. Koup, Q. Paula Lei, John R. Mascola, Reda Rawi, Leonid Serebryannyy, Lawrence Shapiro, Zizhang Sheng, David D. Ho, Patrick C. Wilson, Jonathan W. Yewdell, Theodore C. Pierson, Masaru Kanekiyo, Nicole A. Doria‐Rose, Peter D. Kwong, Tongqing Zhou   +71 more
wiley   +1 more source

Investigation on a Freeze-Drying Process for Long-Term Stability of mRNA-LNPs

Vaccines
Background: Thermostability remains a key bottleneck for equitable access to mRNA-LNPs vaccines, mainly due to cold-chain requirements. Objectives and methods: Here, we optimized freeze-drying formulations by screening excipients (sugars, sugar alcohols,
MD Faizul Hussain Khan, Ayyappasamy Sudalaiyadum Perumal, Amine A. Kamen   +2 more
doaj   +1 more source

Inflammation Unchecked: Concurrent Kawasaki Disease and Stevens‐Johnson Syndrome in an 18‐Month‐Old Child

Arthritis Care &Research, EarlyView.
Catherine Deffendall, Jodi Backalar, Elizabeth Acevedo Zapata, Adriana Della Porta, Lorin Bibb, Tyler Reese, Charlotte M. Brown   +6 more
wiley   +1 more source

Switching Spike Plasticity Shapes ACE2 Engagement Across SARS‐CoV‐2 Variants

Advanced Science, EarlyView.
Conformational plasticity governs SARS‐CoV‐2 spike function and ACE2 recognition. Using high‐speed AFM and single‐molecule force spectroscopy, we analyzed the ancestral spike and nine variants, revealing progressive rigidification from Delta, variable plasticity in Omicron sublineages, and JN.1 compaction.
Sarah Stainer, Rong Zhu, Manuel Reithofer, Gerhard Stadlmayr, Katharina Stadlbauer, Panchika Prangkio, Christoph Rippel, Markus Hahn, Aniko Eva Kasztner, Stefanie Stohl, Petr Bednar, Daniel Ruzek, David Glück, Robert Tampé, Gordana Wozniak‐Knopp, Yoo Jin Oh, Miriam Klausberger, Peter Hinterdorfer   +17 more
wiley   +1 more source

Development of Long-Term Stability of Enveloped rVSV Viral Vector Expressing SARS-CoV-2 Antigen Using a DOE-Guided Approach

Vaccines
Liquid formulations have been successfully used in many viral vector vaccines including influenza (Flu), hepatitis B, polio (IPV), Ebola, and COVID-19 vaccines. The main advantage of liquid formulations over lyophilized formulations is that they are cost-
MD Faizul Hussain Khan, Caroline E. Wagner, Amine A. Kamen   +2 more
doaj   +1 more source